Company / Capital Expenditures
ADMA Biologics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$22.6M
FY2025
5-year range
$4.8M / $22.6M
FY2021-FY2025
Trend
+174.4%
vs FY2024
Sector context
#44 of 194
Health Care
What the data says
ADMA Biologics, Inc.'s capital expenditures of $23M is higher than 77% of companies in the Health Care sector (FY2025). Improved from $5M to $23M over the past 2 years.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of +12.1%. Top quartile in the Health Care sector.
Improved from $5M to $23M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +18.7%
- 5-Year CAGR
- +12.1%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 194This company $22.6M Sector average $117.5M
▼
-80.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.1%, indicating consistent growth.
- In FY2025, capital expenditures increased 174.4% year-over-year.
- Ranks #44 out of 194 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.6M | +174.4% |
| FY2024 | $8.2M | +72.4% |
| FY2023 | $4.8M | -64.7% |
| FY2022 | $13.5M | +0.0% |
| FY2021 | $13.5M | +6.2% |
| FY2020 | $12.7M | +233.9% |
| FY2019 | $3.8M | +81.9% |
| FY2018 | $2.1M | +2754.7% |
| FY2017 | $73.4K | +0.0% |
| FY2016 | $73.4K | -96.8% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026